Corient Private Wealth LP Takes $2.23 Million Position in Twist Bioscience Corporation $TWST

Corient Private Wealth LP purchased a new stake in shares of Twist Bioscience Corporation (NASDAQ:TWST - Free Report) during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor purchased 21,633 shares of the company's stock, valued at approximately $2,226,000.

Several other large investors have also recently added to or reduced their stakes in TWST. Amundi acquired a new position in Twist Bioscience in the second quarter worth $252,000. VIRGINIA RETIREMENT SYSTEMS ET Al bought a new position in shares of Twist Bioscience in the 2nd quarter worth about $1,640,000. AlphaGrep UK Ltd acquired a new position in shares of Twist Bioscience in the 2nd quarter valued at about $229,000. Nykredit A S acquired a new position in shares of Twist Bioscience in the 2nd quarter valued at about $283,000. Finally, Susquehanna Fundamental Investments LLC bought a new stake in shares of Twist Bioscience during the 2nd quarter valued at about $3,517,000.

Twist Bioscience Price Performance

Shares of NASDAQ:TWST opened at $158.50 on Thursday. The company has a debt-to-equity ratio of 0.03, a current ratio of 2.67 and a quick ratio of 2.38. The stock has a market cap of $9.94 billion, a price-to-earnings ratio of -71.40 and a beta of 2.22. The stock's 50 day moving average price is $123.26 and its 200 day moving average price is $85.49. Twist Bioscience Corporation has a 12 month low of $23.30 and a 12 month high of $170.66.

Twist Bioscience (NASDAQ:TWST - Get Free Report) last issued its earnings results on Monday, August 3rd. The company reported ($0.56) earnings per share for the quarter, missing analysts' consensus estimates of ($0.51) by ($0.05). Twist Bioscience had a negative return on equity of 28.64% and a negative net margin of 31.66%.The business had revenue of $118.38 million for the quarter, compared to the consensus estimate of $114.55 million. During the same quarter in the previous year, the business posted $0.33 earnings per share. The company's quarterly revenue was up 23.2% on a year-over-year basis. Equities research analysts anticipate that Twist Bioscience Corporation will post -2.12 earnings per share for the current fiscal year.

Insiders Place Their Bets

In related news, CEO Emily Leproust sold 356,546 shares of the business's stock in a transaction that occurred on Thursday, September 17th. The shares were sold at an average price of $157.99, for a total transaction of $56,330,702.54. Following the transaction, the chief executive officer directly owned 620,589 shares of the company's stock, valued at approximately $98,046,856.11. The trade was a 36.49% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, SVP Paula Green sold 294 shares of the stock in a transaction that occurred on Monday, September 21st. The stock was sold at an average price of $165.49, for a total transaction of $48,654.06. Following the completion of the sale, the senior vice president owned 116,720 shares of the company's stock, valued at approximately $19,315,992.80. The trade was a 0.25% decrease in their position. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold a total of 516,574 shares of company stock valued at $77,493,635 over the last ninety days. Corporate insiders own 3.08% of the company's stock.

Trending Headlines about Twist Bioscience

Here are the key news stories impacting Twist Bioscience this week:

• Positive Sentiment: Twist’s partnership with Lilly TuneLab, Eli Lilly’s AI-driven drug-discovery platform, makes Twist a preferred provider of antibody-characterization data and expands its exposure to AI-enabled pharmaceutical research. Twist Bioscience Expands AI Drug Discovery Exposure With Lilly TuneLab Partnership
• Positive Sentiment: The company’s latest quarterly update showed record revenue of $118.4 million, up 23.2% year over year, and higher full-year revenue guidance. These results provide fundamental support for the recent rally, despite a quarterly loss and an earnings miss.
• Neutral Sentiment: TWST recently reached a new 12-month high after its partnership-driven advance, leaving the stock vulnerable to normal consolidation and profit-taking. Twist Bioscience Hits New 12-Month High
• Neutral Sentiment: Analyst sentiment remains broadly favorable, with a consensus “Moderate Buy” rating, although several published price targets remain well below the current market level. This highlights valuation risk after the stock’s substantial appreciation.
• Negative Sentiment: CEO Emily Leproust sold 1,687 shares, while SVP Paula Green and insider Dennis Cho sold 294 and 348 shares, respectively, at approximately $165.49. The transactions were reportedly made to cover tax withholding on vested equity awards, limiting their negative significance, and each executive retained a large stake. SEC insider transaction filings
• Negative Sentiment: A larger recent sale by Leproust—356,546 shares worth approximately $56.3 million—reduced her direct ownership by roughly 36.5%. Although it was executed under a pre-arranged Rule 10b5-1 plan, the scale of the transaction may weigh on momentum investors. Twist Bioscience CEO Emily Leproust Sells Stock
• Negative Sentiment: Reports indicate no insider purchases and 87 insider sales over the past six months. Combined with TWST’s high-growth valuation and ongoing losses, the selling trend increases concerns about near-term profit-taking and downside risk.

Wall Street Analysts Forecast Growth

A number of brokerages have commented on TWST. Evercore downgraded Twist Bioscience from an "outperform" rating to an "in-line" rating and set a $102.00 target price for the company. in a research note on Monday, July 6th. Barclays raised their price target on Twist Bioscience from $65.00 to $95.00 and gave the stock an "overweight" rating in a report on Wednesday, June 24th. BWS Financial restated a "sell" rating and set a $45.00 price objective on shares of Twist Bioscience in a research note on Friday, September 18th. Guggenheim reaffirmed a "buy" rating on shares of Twist Bioscience in a research report on Monday, August 24th. Finally, UBS Group began coverage on shares of Twist Bioscience in a report on Wednesday, September 9th. They set a "neutral" rating and a $144.00 price target for the company. Eight equities research analysts have rated the stock with a Buy rating, two have given a Hold rating and two have given a Sell rating to the stock. According to data from MarketBeat.com, Twist Bioscience presently has a consensus rating of "Moderate Buy" and a consensus price target of $103.00.

Twist Bioscience Profile

Twist Bioscience Corporation is a biotechnology company that develops and manufactures synthetic DNA using a proprietary silicon-based platform. The company serves researchers and organizations in biotechnology, pharmaceutical development, agriculture, industrial chemicals and academic research.

Its products include synthetic genes, gene fragments, oligonucleotides and DNA libraries used in research, drug discovery, diagnostics development and other applications. Twist also provides next-generation sequencing tools and products, including target-enrichment and sample-preparation solutions, as well as synthetic biology services that support the design and testing of biological systems.

Twist was founded in 2013 and is headquartered in South San Francisco, California.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.